Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Indusatumab, an antibody targeting GUCY2C.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imalumab, an antibody targeting MIF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Denintuzumab, an antibody targeting CD19.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dectrekumab, an antibody targeting IL-13.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abrilumab, an antibody targeting ITGA4B7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vobarilizumab, an antibody targeting IL-6R × Albumin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Timolumab, an antibody targeting AOC3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rivabazumab, an antibody targeting PcrV type III secretion system.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rinucumab, an antibody targeting PDGFRB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Refanezumab, an antibody targeting SIGLEC4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Opicinumab, an antibody targeting LINGO1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Muromonab, an antibody targeting CD3E.